So we fixed it.
Specialist payment solutions for peptide brands dealing with bans, chargebacks, frozen funds, and excessive upfront reserves.
Generic processors treat peptide brands as collateral damage. One policy change and revenue stops — with your money sitting on the wrong side of the freeze.
Mainstream processors classify peptides as prohibited and terminate accounts overnight — no warning, no recourse.
High dispute ratios push you over thresholds, triggering fines, monitoring programs, and eventual termination.
Settlements get held for 90–180 days "for review," choking the cash flow your business runs on.
Rolling reserves of 10–20% lock away working capital you've already earned — indefinitely.
We build resilient acquiring for brands the mainstream rejects — engineered around the exact failure points that shut peptide businesses down.
Your volume is spread across redundant banking partners that understand peptides. If one path tightens, traffic reroutes — no shutdown, no downtime.
Real-time alerts, automated representment, and dispute deflection keep your ratios under threshold.
Transparent reserve terms and daily settlement keep your working capital working. No indefinite holds.
Every transaction, settlement, and reserve in one dashboard — full visibility into the money that used to disappear behind a freeze.
Customers check out the way they always do. Behind them sits a redundant global settlement network so your revenue never stalls.
Tokenizes every transaction and routes it to the healthiest settlement path in real time.
Customers only ever pay the way they already do — credit, debit, Apple Pay, Google Pay. The settlement complexity stays entirely on our side.
We've spent years inside the high-risk underwriting that makes or breaks peptide brands. You get a specialist team that already knows your model, your risk profile, and the banks willing to back you.
Tell us about your peptide brand — we'll come back with approval odds, rates, reserve terms, and a timeline.